title: Heterogeneity of molecular markers in chronic myelomonocytic leukemia: a disease associated with several gene alterations.
abstract: The relatively homogenous clinical features and poor prognosis of chronic myelomonocytic leukemia (CMML) are associated with a molecular heterogeneity, with various mutations impacting several convergent pathways. Due to the restricted understanding of the mechanism involved in leukemogenesis, CMML still appears as a diagnostic and therapeutic undertaking, and poor prognosis of leukemia. Contrary to chronic myelogenous leukemia, BCR-ABL1-positive, cytogenetic, and molecular abnormalities of CMML are not specific and not pathognomonic, confirming the different levels of heterogeneity of this disease. Various mutations can be associated with a common phenotype not distinct at the clinical level, further demonstrating that molecular probings are needed for choosing individual targeted therapies.
authors.affiliation: Faculté de Médecine, Inserm UMR 866, Université de Bourgogne, 7 bd Jeanne d'Arc, 21000, Dijon, France.
authors.forename: Jean-Noël
authors.initials: JN
authors.lastname: Bastie
authors.forename: Romain
authors.initials: R
authors.lastname: Aucagne
authors.forename: Nathalie
authors.initials: N
authors.lastname: Droin
authors.forename: Eric
authors.initials: E
authors.lastname: Solary
authors.forename: Laurent
authors.initials: L
authors.lastname: Delva
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics*; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D009363:Neoplasm Proteins / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion